Article
Biochemistry & Molecular Biology
Monica Cejuela, Begona Martin-Castillo, Javier A. Menendez, Sonia Pernas
Summary: Breast cancer is the most common cancer among women worldwide, and metabolic traits associated with type 2 diabetes such as hyperglycemia, hyperinsulinemia, inflammation, oxidative stress, and obesity are known risk factors. Metformin, a widely prescribed medication for diabetes, has been suggested to have anti-tumor effects based on previous studies. However, recent randomized controlled trials have shown disappointing results, particularly in metastatic breast cancer. This article reviews the mechanisms of action of metformin, discusses past and current clinical trials, and briefly explores future perspectives for incorporating metformin into the prevention and treatment of breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Domenica Scordamaglia, Francesca Cirillo, Marianna Talia, Maria Francesca Santolla, Damiano Cosimo Rigiracciolo, Lucia Muglia, Azzurra Zicarelli, Salvatore De Rosis, Francesca Giordano, Anna Maria Miglietta, Ernestina Marianna De Francesco, Veronica Vella, Antonino Belfiore, Rosamaria Lappano, Marcello Maggiolini
Summary: This study investigated the role of metformin in inhibiting the growth and metastasis of breast cancer cells and demonstrated its potential as a comprehensive therapeutic approach for breast cancer patients with metabolic disorders.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Oncology
Mihong Choi, Jiyeon Han, Bo Ram Yang, Myoung-jin Jang, Miso Kim, Dae-Won Lee, Tae-Yong Kim, Seock-Ah Im, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Kyung-Hun Lee
Summary: Insulin or statin use prior to breast cancer diagnosis is associated with increased all-cause mortality. Subsequent analysis suggests metformin or statin use may be protective in patients with ER-negative disease, warranting further studies.
CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. Van't Veer, Donald A. Berry, Laura J. Esserman
Summary: The study found that further development of anti-IGF-1R therapy will require better control of drug-induced hyperglycemia and the development of more predictive biomarkers.
Article
Physiology
Gina N. Calco, Becky J. Proskocil, David B. Jacoby, Allison D. Fryer, Zhenying Nie
Summary: Increased insulin levels are associated with obesity-related airway hyperreactivity and asthma. Metformin, an antidiabetic drug, was found to prevent the development of airway hyperreactivity in male rats on a high-fat diet by reducing circulating insulin levels. This study suggests that insulin-targeting medications may be an effective treatment for obesity-related asthma.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
(2021)
Review
Oncology
Laura Garcia-Estevez, Javier Cortes, Silvia Perez, Isabel Calvo, Isabel Gallegos, Gema Moreno-Bueno
Summary: Breast cancer is the most common tumor in women globally, and the relationship between obesity and breast cancer risk is closely related to menopausal status. Obesity increases the risk of breast cancer in postmenopausal women but appears to be protective in premenopausal women.
FRONTIERS IN ONCOLOGY
(2021)
Article
Physiology
Chenjuan Gu, Jeff Loube, Rachel Lee, Shannon Bevans-Fonti, Tianshi David Wu, Jessica H. Barmine, Jonathan C. Jun, Meredith C. McCormack, Nadia N. Hansel, Wayne Mitzner, Vsevolod Y. Polotsky
Summary: The study aimed to investigate the effect of metformin on airway hyperresponsiveness (AHR) in a mouse model of obese asthma. The results showed that metformin can alleviate AHR without affecting body weight or blood glucose levels.
FRONTIERS IN PHYSIOLOGY
(2022)
Article
Health Care Sciences & Services
Seung In Seo, Tae Jun Kim, Chan Hyuk Park, Chang Seok Bang, Kyung Joo Lee, Jinseob Kim, Hyon Hee Kim, Woon Geon Shin
Summary: This study found that the use of metformin in patients with diabetes may reduce the risk of colorectal cancer incidence and improve overall survival, based on an analysis of the Korean National Health Insurance Service database.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Medicine, Research & Experimental
Morteza Gholami, Zeynab Nickhah Klashami, Pirooz Ebrahimi, Amir Ali Mahboobipour, Amir Salehi Farid, Aida Vahidi, Marziyeh Zoughi, Mojgan Asadi, Mahsa M. Amoli
Summary: This comprehensive study aims to review the association between long non-coding RNAs (lncRNAs) and breast cancer (BC) features, and identify metformin-regulated lncRNAs and their mechanisms of action in BC and other types of cancers. The study found that metformin affects BC by regulating five BC-associated lncRNAs including GAS5, HOTAIR, MALAT1, and H19, through several molecular mechanisms. Additionally, metformin also acts on other types of cancers by regulating ten lncRNAs.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Soumya G. Chikermane, Manvi Sharma, Susan M. Abughosh, Rajender R. Aparasu, Meghana Trivedi, Michael L. Johnson
Summary: This study aimed to assess the impact of metformin on the risk of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer in postmenopausal women. The results showed that higher cumulative dose and intensity of metformin exposure were associated with a reduced risk of HR+/HER2- breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Endocrinology & Metabolism
Jiamei Le, Yi Fu, Qiuqin Han, Xindong Wei, Houlin Ji, Yifan Chen, Qiuying Wang, Peixian Pi, Jilei Li, Xinjie Lin, Xiaoying Zhang, Yong Zhang, Jianping Ye
Summary: Metformin improves insulin sensitivity in type 2 diabetes by targeting liver, intestine, and other organs. This study found that more genes were altered in the liver than in the colon of diet-induced obese mice, with 20 Slc genes confirmed to be altered in the liver and 15 of them restored by MET, leading to improved insulin sensitivity and obesity.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Megan M. Kelsey, Allison Hilkin, Laura Pyle, Cameron Severn, Kristina Utzschneider, Rachael E. Van Pelt, Philip S. Zeitler, Kristen J. Nadeau
Summary: Metformin treatment during puberty in obese youth improved BMI and body fat, but did not affect insulin sensitivity or beta-cell function. High DI in early puberty may predict a decline in DI later on, highlighting the need for further research on preserving beta-cell function in at-risk youth for type 2 diabetes.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Chemistry, Multidisciplinary
Jie Chen, Jee Young Chung, Huapan Fang, Lin Lin, Yong-Hee Kim, Huayu Tian, Xuesi Chen
Summary: Obesity is a significant public health problem that needs to be urgently addressed. This study presents a potential effective strategy for the clinical treatment of obesity, using an adipocyte-targeting gene carrier combined with metformin to achieve body weight reduction and metabolic recovery.
SCIENCE CHINA-CHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Elizabeth R. M. Zunica, Christopher L. Axelrod, John P. Kirwan
Summary: Breast cancer is a common and deadly disease, with better prognosis for early-stage and less aggressive subtypes. However, aggressive subtypes have limited treatment options and responses, leading to decreased survival. Phytochemicals, with chemopreventive, therapeutic, and sensitizing properties, have the potential for treatment, management, and prevention of breast cancer. Targeting mitochondria, phytochemicals can enhance anti-breast cancer efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Courtney Macdonald, James A. Chamberlain, Danielle Mazza, Roger L. Milne, Kelly-Anne Phillips
Summary: The study found that only a small percentage of Australian women have used breast cancer risk reducing medication, with higher breast cancer risk significantly associated with the use of such medication, while factors like parity, education level, and family history were not correlated. Efforts are needed to incorporate breast cancer risk assessment and management discussions into routine health assessments for women.
Meeting Abstract
Oncology
Isabel Pimentel, Bingshu E. Chen, Ana Elisa Lohmann, Marguerite Ennis, Jennifer A. Ligibel, Lois E. Shepherd, Dawn L. Hershman, Vuk Stambolic, Ingrid A. Mayer, Timothy J. Hobday, Julie Lemieux, Alastair Mark Thompson, Priya Rastogi, Karen A. Gelmon, Timothy Joseph Whelan, Manuela Rabaglio-Poretti, Ryan Jo Dowling, Wendy R. Parulekar, Pamela Jean Goodwin
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Biology
Bert van de Kooij, Pau Creixell, Anne van Vlimmerent, Brian A. Joughin, Chad J. Miller, Nasir Haider, Craig D. Simpson, Rune Linding, Vuk Stambolic, Benjamin E. Turk, Michael B. Yaffe
Article
Oncology
Isabel Pimentel, Ana Elisa Lohmann, Marguerite Ennis, Ryan J. O. Dowling, David Cescon, C. Elser, K. R. Potvin, R. Haq, C. Hamm, Martin C. Chang, Vuk Stambolic, Pamela J. Goodwin
Article
Oncology
Isabel Pimentel, Bingshu E. Chen, Ana Elisa Lohmann, Marguerite Ennis, Jennifer Ligibel, Lois Shepherd, Dawn L. Hershman, Timothy Whelan, Vuk Stambolic, Ingrid Mayer, Timothy Hobday, Julie Lemieux, Alastair Thompson, Priya Rastogi, Karen Gelmon, Daniel Rea, Manuela Rabaglio, Susan Ellard, Mihaela Mates, Philippe Bedard, Lacey Pitre, Theodore Vandenberg, Ryan J. O. Dowling, Wendy Parulekar, Pamela J. Goodwin
Summary: The study found that metformin can decrease estradiol levels independently of BMI, suggesting a potential new effect of metformin that may be relevant to estrogen-sensitive cancers.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Editorial Material
Oncology
Ana Elisa Lohmann, Pamela J. Goodwin
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Biochemistry & Molecular Biology
Nasir Haider, Previn Dutt, Bert van de Kooij, Jason Ho, Luis Palomero, Miquel Angel Pujana, Michael Yaffe, Vuk Stambolic
Editorial Material
Oncology
Pamela J. Goodwin
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2021)
Article
Oncology
Pamela J. Goodwin, Ryan J. O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Margot J. Burnell, Rachel Vander Meer, Andrea Molckovsky, Anagha Gurjal, Karen A. Gelmon, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Whelan, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alastair M. Thompson, Daniel W. Rea, Vuk Stambolic
Summary: The study demonstrates that metformin compared to placebo leads to significant weight and metabolic improvements in breast cancer patients, with no influence from baseline BMI or insulin, and no differences based on the rs11212617 allele status.
Article
Oncology
Martin C. Chang, Zohreh Eslami, Marguerite Ennis, Pamela J. Goodwin
Summary: Crown-like structures of the breast (CLS-B) are positively correlated with older age, obesity, dyslipidemia, and higher levels of metabolic factors, while different methods of detecting CLS-B show different associations with metabolic factors, disease-free survival, and overall survival. Further research is needed to understand the biological basis for these differences.
Article
Oncology
Ana Elisa Lohmann, Marguerite Ennis, Wendy R. Parulekar, Bingshu E. Chen, George Tomlinson, Pamela J. Goodwin
Summary: Interim analysis plays a role in terminating exposure to ineffective or unsafe drugs while identifying effective treatments. However, in breast cancer treatment, early analysis may overlook the effects that can only be observed with longer follow-up.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Editorial Material
Oncology
Pamela J. Goodwin
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Dawn L. Hershman, Bingshu E. Chen, Wendy R. Parulekar, Julie Lemieux, Jennifer A. Ligibel, Karen A. Gelmon, Timothy Joseph Whelan, Pamela Jean Goodwin
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Pamela J. Goodwin, Ryan J. O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Karen A. Gelmon, Timothy J. Whelan, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alastair M. Thompson, Daniel W. Rea, Vuk Stambolic
Summary: The study showed that metformin significantly reduces CA 15-3 levels in early-stage breast cancer patients. This reduction is independent of tumor characteristics and treatment methods.
JNCI CANCER SPECTRUM
(2021)
Article
Oncology
Pamela J. Goodwin, Roanne J. Segal, Michael Vallis, Jennifer A. Ligibel, Gregory R. Pond, Andre Robidoux, Brian Findlay, Julie R. Gralow, Som D. Mukherjee, Mark Levine, Kathleen I. Pritchard
Meeting Abstract
Oncology
Ana Elisa Lohmann, Sara V. Soldera, Isabel Pimentel, Domen Ribnikar, Marguerite Ennis, Eitan Amir, Pamela Jean Goodwin
JOURNAL OF CLINICAL ONCOLOGY
(2019)